Berlin/Breda, 13 October 2026. Eckert & Ziegler Brazil, a regional subsidiary of the global nuclear medicine group Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), and TerThera announced today the signing of a strategic supply agreement for the precursor Terbium-161.

Under the terms of the agreement, TerThera will supply its GMP-compliant non-carrier-added (n.c.a.) Terbium-161 (Tb-161) to Eckert & Ziegler Brazil. This partnership establishes a critical and reliable supply chain for the innovative isotope in South America, directly providing Brazilian patients access to the next generation of radioligand therapies. Moreover, the availability of GMP-grade Tb-161 will allow local pharmaceutical developers and clinical institutions to investigate the combination of Tb-161 with novel peptides, antibodies, and FAP-inhibitors to target a broad spectrum of oncological indications. The agreement, between Eckert & Ziegler Brazil and TerThera, will bring the next generation of Radioligand Therapy (RLT)  to Brazil and allow access to a novel radiopharmaceutical for cancer healthcare.

Terbium-161, a carrier free lanthanide produced by neutron activation, is a highly promising radionuclide for Radioligand Therapy (RLT) exhibiting comparable chemical characteristics to known radiolanthanides that has the potential, due to highest addition of Auger electronic emission with a higher linear energy transfer, to improve anti-tumor capabilities for primary and (micro)metastasized cancers. The latest clinical results has shown a promising and effective anti-tumor response, even after treatment stops of conventional medicine, providing for a new therapy option by depositing a highest but localized tumor dose with limited impact on healthy tissue.

Expanding Local Theranostic Infrastructure
“It is a great milestone that after six years of absence we are back in Brazil with a potentially better radionuclide,” said Philippe van Overeem, CEO of TerThera. “Having supplied Lu-177 to Brazil for almost two decades, I know firsthand the passion and capability of the local nuclear medicine community. Returning to this market with GMP-grade Terbium-161 allows us to build on that legacy and give Brazilian doctors and researchers a powerful, next-generation tool to treat micro-metastases and complex tumors more effectively.”

The agreement leverages Eckert & Ziegler’s robust presence in Latin America, combining TerThera’s unique isotope production capabilities with a powerful regional distribution and manufacturing network.

“We are proud to partner with TerThera to bring this highly promising isotope to South America,” stated Fabrício Diel, the Managing Director of Eckert & Ziegler Brazil. “Integrating Terbium-161 into our portfolio perfectly aligns with our mission of Contributing to Saving Lives and our goal to expand local access to strategic theranostic solutions. By combining this premium radionuclide with advanced targeting agents here in Brazil, we are shortening the supply chain and opening new clinical horizons for oncology patients across the region.”

About TerThera BV
TerThera is a radionuclide production focused company based in The Netherlands. The founders and the staff of TerThera have decades of experience in the nuclear medicine industry and are giving their full focus on the production of the innovative radionuclide Terbium-161 (Tb-161). TerThera is building a global platform to meet the growing demand for radionuclides in oncology and nuclear medicine. www.terthera.com

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
www.ezag.com

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

A landmark study published in Frontiers in Medicine by Albano, Paone, and Treglia delivers critical clinical validation for hospitals looking to adopt next-generation radioligand therapy. As the first-ever systematic review and meta-analysis of its kind, the study analyzed data from 80 metastatic castration-resistant prostate cancer (mCRPC) patients across 291 cycles. It conclusively proves that Terbium-161 (Tb-161) is not only highly effective but also exceptionally safe.

The clinical outcomes provide a compelling case for nuclear medicine departments. The pooled analysis demonstrated a remarkable 83.9% disease control rate and a 50.2% objective PSA response rate. Crucially, this high efficacy was maintained in late-stage patients who had previously failed conventional Lutetium-177 or Actinium-225 therapies, proving that Tb-161 can overcome established resistance pathways. Despite this powerful therapeutic effect, severe side effects were rare, confirming that the treatment fits safely and seamlessly into existing outpatient and inpatient hospital workflows.

This clinical advantage is driven by the unique physics of Terbium-161. By co-emitting medium-range beta particles and short-range Auger and conversion electrons, it delivers a massive, highly localized energy dose. This dual action successfully eradicates single cancer cells and micrometastases that traditional beta-only emitters often miss. Since Terbium-161 shares identical chelator chemistry with Lutetium-177, your hospital can easily adopt these protocols using your existing radiopharmacy infrastructure. Partner with TerThera today to secure a reliable, commercial-scale supply of high-purity Terbium-161 for your clinic.

TerThera B.V. has achieved a major new milestone by producing over 25,000 GBq (675 Ci) of Terbium-161. Thanks to this record-breaking production, the crucial precursor is now available in abundance on a full global scale, supplying clinical trials and multiple R&D pipelines across six continents. Since its launch in 2022, TerThera has been fully dedicated to making this isotope widely available, a mission that is now accelerated by a rapidly increasing demand from hospitals, biotech companies, and Big Pharma alike.

In his role as Radiochemist, Edwin will be instrumental in the development and manufacturing of the medical radioisotope Terbium-161 which is today being adopted for Radioligand Therapy (RLT) on a global scale providing for a novel and promising therapy.
“The therapeutical value of Terbium-161 is extremely potent and will become the next generation of RLT, and I’m therefore proud to be part of the TerThera team dedicated to bringing Tb-161 to the patient,” said Edwin Pietersveld, Radiochemist at TerThera b.v.

Starting in his role as Project Manager, Dejan brings extensive experience in site creation and over a decade of experience in the production of radiopharmaceuticals. As the lead in key projects, Dejan will be responsible for the finalization of our newly built production site and provide support in the production of Terbium-161 GMP.

“I’m really grateful and excited to take on this challenge and looking forward to helping bring the Tb161 production site to completion. What makes it even more special is the chance to reunite with colleagues with whom I’ve already shared great successes in the past. I can’t wait to achieve new milestones together!” said Dejan Čatlaić, Project Manager at TerThera b.v.

TerThera B.V. has officially launched the world’s first GMP-compliant Terbium-161 NCA, setting a new benchmark in the commercial scale production of this promising radionuclide.

Milestone reached. With the extended geographical reach, we were able to meet the demand for Terbium-161 (Tb-161) on 6 continents by ramping up the production that has led to reaching the threshold 200Ci or 7.4TBq Terbium-161 produced and expedited.

Imke will have an instrumental role as Quality and Validation Engineer to further strengthen the hashtag#Terbium161 platform, safeguarding the highest level of quality and preparing our processes for the next scale-up phase. “Amazing to join TerThera in such a significant role and to experience the impact of a novel and groundbreaking radionuclide, both from an academic and industrial perspective,” said Imke Boekestijn, Quality and Validation Engineer at TerThera.